Third set of teeth: can tooth regeneration become a reality by 2030?

For decades, tooth loss has been viewed as an irreversible process requiring exclusively substitutive solutions—removable dentures, bridges, or dental implants. Despite significant progress in implantology and prosthetic dentistry, all existing methods remain artificial replacements, not a restoration of the lost organ. However, modern advancements in molecular biology and regenerative medicine are challenging this long-standing notion. Clinical research being conducted in Japan points to the possibility of a fundamentally new approach—stimulating the growth of new, biologically complete teeth in humans.

Biological foundations of tooth growth and the role of the USAG-1 protein

The current research is based on the study of the USAG-1 protein, which plays a key role in regulating odontogenesis. Normally, this protein restricts the development of tooth buds, preventing the formation of an excessive number of teeth. Japanese scientists have proposed the hypothesis that suppressing the activity of USAG-1 could release this biological “brake” and activate hidden tooth growth mechanisms.

Experimental studies on animals have confirmed the viability of this concept. Laboratory mice treated with a drug blocking USAG-1 exhibited the growth of additional teeth, which in structure and function corresponded to natural ones. These results became a turning point, demonstrating that mammals possess a latent capacity for tooth reformation that remains suppressed under normal conditions.

Potential for tooth regeneration in humans

Of particular interest is the fact that, according to modern understanding, humans have so-called “dormant” tooth buds for a third set of teeth in their jaws. Unlike primary and permanent teeth, they do not develop due to the action of regulatory molecular mechanisms. The new therapy specifically targets the activation of these buds, which in theory could lead to the growth of new teeth without the need for surgical implantation.

If the data obtained from preclinical studies are confirmed in clinical trials, it will open completely new horizons for dentistry. This technology could become particularly significant for patients with anodontia — a rare genetic disorder characterized by the absence of part or the entire dentition. For such patients, regenerative therapy could become the first etiological treatment, rather than merely a method of compensating for the defect.

Potential changes in clinical practice

The emergence of a pharmacological method for tooth restoration has the potential to alter the very philosophy of dental treatment. Instead of replacing lost structures with artificial constructs, the focus may shift towards biological restoration and prevention. This, in turn, would necessitate a revision of diagnostic protocols, intervention timing, and approaches to long-term patient monitoring.

For practicing dentists and orthodontists, such therapy could become a third treatment modality alongside prosthetics and implantation. In a broader perspective, it would also impact the system of dental education, as the importance of molecular biology, genetics, and regenerative medicine in specialist training would increase.

Ethical and scientific challenges

Despite optimistic forecasts, researchers emphasize that a significant journey still lies ahead before widespread clinical application. It is essential to thoroughly evaluate the therapy’s safety, the controllability of tooth growth, potential side effects, and the long-term consequences of interfering with tissue development regulatory mechanisms. Additionally, questions regarding patient age, optimal timing for drug administration, and individual variations in treatment response remain open.

Conclusion: regenerative dentistry as the medicine of the future

Research being conducted in Japan indicates that the idea of growing a third set of teeth is ceasing to be science fiction and gradually transitioning into the realm of clinical reality. If the stated goals are achieved and the drug reaches the market by 2030, dentistry may enter a new era where tooth loss will be viewed as a reversible condition. This opens prospects not only for improving the quality of life for millions of people but also for establishing a fundamentally new approach to the treatment and prevention of oral diseases in the 21st century.